Learned lessons from patients who take clozapine: A case study.

Related Articles
Learned lessons from patients who take clozapine: A case study.
Perspect Psychiatr Care. 2017 Sep 19;:
Authors: Lee H, Scolieri BB, Mullick PK
Abstract
PURPOSE: The purpose of this r…

read more

Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.

Related Articles
Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.
Neuropsychiatr Dis Treat. 2017;13:2285-2296
Authors: Sajatovic M, DiBiasi F,…

read more

Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.

Related Articles
Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.
Neuropsychiatr Dis Treat. 2017;13:2285-2296
Authors: Sajatovic M, DiBiasi F,…

read more

Rapgef2, a guanine nucleotide exchange factor for Rap1 small GTPases, plays a crucial role in adherence junction (AJ) formation in radial glial cells through ERK-mediated upregulation of the AJ-constituent protein expression.

Related Articles

Rapgef2, a guanine nucleotide exchange factor for Rap1 small GTPases, plays a crucial role in adherence junction (AJ) formation in radial glial cells through ERK-mediated upregulation of the AJ-constituent protein expression.

Biochem Biophys Res Commun. 2017 Sep 13;:

Authors: Farag MI, Yoshikawa Y, Maeta K, Kataoka T

Abstract
Rapgef2 and Rapgef6 define a subfamily of guanine nucleotide exchange factors for Rap1, characterized by possession of the Ras/Rap-associating domains and implicated in the etiology of schizophrenia. We previously found that dorsal telencephalon-specific Rapgef2 conditional knockout mice exhibits severe defects in formation of apical surface adherence junctions (AJs) and localization of radial glial cells (RGCs). In this study, we analyze the underlying molecular mechanism by using primary cultures of RGCs established from the developing cerebral cortex. The results show that Rapgef2-deficient RGCs exhibit a decreased ability of neurosphere formation, morphological changes represented by regression of radial glial (RG) fibers and reduced expression of AJ-constituent proteins such as N-cadherin, zonula occludens-1, E-cadherin and β-catenin. Moreover, siRNA-mediated knockdown of Rapgef2 or Rap1A inhibits the AJ protein expression and RG fiber formation while overexpression of Rapgef2, Rapgef6, Rap1A(G12V) or Rap1B(G12V) in Rapgef2-deficient RGCs restores them. Furthermore, Rapgef2-deficient RGCs exhibit a reduction in phosphorylation of extracellular signal-regulated kinase (ERK) leading to downregulation of the expression of c-jun, which is implicated in the AJ protein expression. These results indicate a crucial role of the Rapgef2-Rap1A-ERK-c-jun pathway in regulation of the AJ formation in RGCs.

PMID: 28917843 [PubMed – as supplied by publisher]

read more

Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis.

Related Articles
Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis.
J Affect Disord. 2017 Sep 07;225:665-670
Authors: Ayerbe L, Forgnone I,…

read more

Impact of stress response in development of first-episode psychosis in schizophrenia: An overview of systematic reviews.

Related Articles
Impact of stress response in development of first-episode psychosis in schizophrenia: An overview of systematic reviews.
Psychiatr Danub. 2017 Mar;29(1):14-23
Authors: Gajsak LR, Gelemanovic A, Kuzm…

read more

Mindfulness-Based Treatment for Bipolar Disorder: A Systematic Review of the Literature.

Related Articles
Mindfulness-Based Treatment for Bipolar Disorder: A Systematic Review of the Literature.
Eur J Psychol. 2017 Aug;13(3):573-598
Authors: Bojic S, Becerra R
Abstract
Despite the increa…

read more

Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs.

Related Articles
Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs.
Transl Psychiatry. 2017 Sep 12;7(9):e1232
Authors: Lancee M, Lemmens CMC, Kahn RS, Vinkers CH, Luykx JJ

read more

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Related Articles

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Neuropsychopharmacology. 2016 Nov;41(12):2893-2902

Authors: Haig G, Wang D, Othman AA, Zhao J

Abstract
A double-blind, placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy and safety of 3 doses of ABT-126, an α7 nicotinic receptor agonist, for the treatment of cognitive impairment in nonsmoking subjects with schizophrenia. Clinically stable subjects were randomized in 2 stages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage 2). The primary analysis was the change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score for ABT-126 50 mg vs placebo using a mixed-model for repeated-measures. A key secondary measure was the University of California Performance-based Assessment-Extended Range (UPSA-2ER). A total of 432 subjects were randomized and 80% (344/431) completed the study. No statistically significant differences were observed in either the change from baseline for the MCCB neurocognitive composite score (+2.66 [±0.54] for ABT-126 50 mg vs +2.46 [±0.56] for placebo at week 12; P>0.05) or the UPSA-2ER. A trend for improvement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total score for ABT-126 50 mg (change from baseline -4.27±[0.58] vs -3.00±[0.60] for placebo; P=0.059). Other secondary analyses were generally consistent with the primary end point results. Adverse event rates were similar for ABT-126 and placebo. ABT-126 did not demonstrate a consistent effect on cognition in nonsmoking subjects with schizophrenia; however, a trend toward an effect was observed on negative symptoms. ClincalTrials.gov registration: NCT01655680.

PMID: 27319970 [PubMed – indexed for MEDLINE]

read more

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Related Articles

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Neuropsychopharmacology. 2016 Nov;41(12):2893-2902

Authors: Haig G, Wang D, Othman AA, Zhao J

Abstract
A double-blind, placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy and safety of 3 doses of ABT-126, an α7 nicotinic receptor agonist, for the treatment of cognitive impairment in nonsmoking subjects with schizophrenia. Clinically stable subjects were randomized in 2 stages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage 2). The primary analysis was the change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score for ABT-126 50 mg vs placebo using a mixed-model for repeated-measures. A key secondary measure was the University of California Performance-based Assessment-Extended Range (UPSA-2ER). A total of 432 subjects were randomized and 80% (344/431) completed the study. No statistically significant differences were observed in either the change from baseline for the MCCB neurocognitive composite score (+2.66 [±0.54] for ABT-126 50 mg vs +2.46 [±0.56] for placebo at week 12; P>0.05) or the UPSA-2ER. A trend for improvement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total score for ABT-126 50 mg (change from baseline -4.27±[0.58] vs -3.00±[0.60] for placebo; P=0.059). Other secondary analyses were generally consistent with the primary end point results. Adverse event rates were similar for ABT-126 and placebo. ABT-126 did not demonstrate a consistent effect on cognition in nonsmoking subjects with schizophrenia; however, a trend toward an effect was observed on negative symptoms. ClincalTrials.gov registration: NCT01655680.

PMID: 27319970 [PubMed – indexed for MEDLINE]

read more
Page 1 of 12212345»102030...Last »

Log In